SYNCURINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Syncurine, and what generic alternatives are available?
Syncurine is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in SYNCURINE is decamethonium bromide. Additional details are available on the decamethonium bromide profile page.
Summary for SYNCURINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 55 |
Patent Applications: | 493 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SYNCURINE at DailyMed |
US Patents and Regulatory Information for SYNCURINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | SYNCURINE | decamethonium bromide | INJECTABLE;INJECTION | 006931-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |